ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy
- 1 June 2003
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 46 (6), 856-868
- https://doi.org/10.1007/s00125-003-1106-8
Abstract
It was the aim of our study to investigate the influence of a selective ET-A receptor antagonist LU 135252 alone and in combination with the ACE-inhibitor, trandolapril on podocyte number and morphology in streptozotocin diabetic rats.Keywords
This publication has 36 references indexed in Scilit:
- Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockersKidney International, 2001
- Glomerular cell number in normal subjects and in type 1 diabetic patientsKidney International, 2001
- Association of Prolonged Hyperglycemia With Glomerular Hypertrophy and Renal Basement Membrane Thickening in the Goto Kakizaki Model of Non–Insulin-Dependent Diabetes MellitusAmerican Journal of Kidney Diseases, 2001
- Increased Expression of Endothelin-1 and Inducible Nitric Oxide Synthase Isoform II in Aging Arteries in Vivo: Implications for AtherosclerosisBiochemical and Biophysical Research Communications, 2001
- Diabetes mellitus increases endothelin-1 gene transcription in rat kidneyKidney International, 2000
- Endothelin receptor antagonists influence cardiovascular morphology in uremic ratsKidney International, 1999
- Podocyte loss and progressive glomerular injury in type II diabetes.Journal of Clinical Investigation, 1997
- Endothelins in the normal and diseased kidneyAmerican Journal of Kidney Diseases, 1997
- Mitosis and the Presence of Binucleate Cells among Glomerular Podocytes in Diseased Human KidneysNephron, 1995
- G 1 Events and Regulation of Cell ProliferationScience, 1989